CLINUVEL implements strategic reorganisation to refocus on U.S. market 2026 Announcements . Corporate . News . Regulatory 23.07.2026
CLINUVEL’s ADS commences trading on Nasdaq 2026 Announcements . Corporate . News . Regulatory 21.07.2026
CLINUVEL’s ADS to commence trading on Nasdaq 2026 Announcements . Corporate . News . Regulatory 20.07.2026
CLINUVEL confirms terms of CEO’s Employment Agreement 2026 Announcements . Corporate . News 02.07.2026
CLINUVEL publicly files 20-F Registration Statement to U.S. SEC 2026 Announcements . Corporate . Financial . News . Regulatory 16.06.2026
CLINUVEL non-deal roadshow presentation deck 2026 Announcements . Corporate . News . Presentation 02.06.2026
Appendix 3G — Notification on unquoted securities 2026 Announcements . Financial . News . Regulatory 07.05.2026
CLINUVEL: update on Level II ADR upgrade, Nasdaq uplist 2026 Announcements . Clinical . News 28.04.2026
CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study 2026 Announcements . Clinical . News 24.04.2026
Appendix 3H — Notification of cessation of securities 2026 Announcements . Financial . News . Regulatory 17.04.2026
CLINUVEL: advancing peptides for photomedicine and vitiligo care at AAD 2026 2026 Announcements . Corporate . News 15.04.2026